The DOI matches its Crossref record.
Pharmacological Treatment and Neurobiology of Hypochondriasis, Illness Anxiety, and Somatic Symptoms
Abstract
The chapter presents the principles of pharmacological treatment of hypochondriasis and addresses practical issues such as resistance to medication treatment, management of side effects, and duration and cessation of pharmacotherapy. A relatively small number of studies suggest that pharmacological treatment is a viable option for patients with hypochondriasis. Although pharmacotherapy trials have not yet been conducted in patients meeting criteria for the new DSM-5 categories of illness anxiety disorder and somatic symptom disorder, it appears that serotonin reuptake inhibitors are suitable for the former, whereas serotonin and norepinephrine reuptake inhibitors may be indicated for the latter. There is little understanding of the neurobiology of hypochondriasis, but emerging models point to links with obsessive-compulsive disorder and possible psychoneuroimmunological underpinnings of somatic amplification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People who are severely anxious about their health or develop a full-blown hypochondriasis may need further psychological treatment that specifically addresses their bodily concerns (Bouman, 2014); sometimes, this approach can be accompanied by antidepressants (Harding & Fallon, 2014).”
From The four horsemen of fear: An integrated model of understanding fear experiences during the COVID-19 pandemic (2020) · cites this paper as Harding & Fallon, 2014
Citations
Cited by
Sorted by citations
Schimmenti, A., Billieux, J., & Starcevic, V. (2020) · PubMed Central · doi:10.36131/cn20200202 · Cited by 313
Metadata
- Authors
- Harding, K. J. K., & Fallon, B. A.
- ORCID
- Fallon, Brian A.
- Venue
- Hypochondriasis and Health Anxiety
- Publisher
- Oxford University Press
- Published
- 2014-05
- Pages
- 241-258
- OpenAlex
- W2486120314
- Cited by
- 3
- References
- 0
- Citations by year
- 2023: 1 · 2020: 1 · 2015: 1
- FWCI
- 1.67
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Oxford University Press eBooks (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- health anxiety, somatic symptom disorder, pharmacotherapy, serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, drug resistance, adverse drug reactions, treatment duration, neurobiology, obsessive-compulsive disorder, psychoneuroimmunology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
